Supplemental Table 5. Associations between aging constructs and mortality in cancer survivors and controls; cancer cases diagnosed within two years of blood collection were excluded, HRS (2016-2020) Sample A^a

	Cancer survivors (N =	= <i>845)</i> ^b		
Aging constructs	No. of deaths	Total	HR (95% CI) per 1 SD increase in aging constructs	
		person-year	Model 2 ^d	Model 2 ^d
KDM-BA-Accel (SD = 4.02 years)	108	3,379	1.14 (0.95, 1.36)	1.08 (0.89, 1.30)
PhenoAgeAccel (SD = 7.19 years)			1.47 (1.13, 1.91)	1.44 (1.07, 1.94)
SA-Accel ($SD = 10.33 years$)			0.99 (0.68, 1.43)	0.93 (0.65, 1.34)
	Controls ($N = 4,46$	51) ^b		
Aging constructs	No. of deaths	Total	HR (95% CI) per 1 SD increase in aging constructs	
		person-year	Model 2 ^d	Model 2 ^d
KDM-BA-Accel (SD = 3.77 years)	242	18,468	1.39 (1.20, 1.61)	1.32 (1.10, 1.59)
PhenoAgeAccel (SD = 7.09 years)			1.46 (1.29, 1.66)	1.41 (1.21, 1.65)
SA-Accel ($SD = 10.37 years$)			1.24 (0.98, 1.55)	1.20 (0.98, 1.46)
	Sample B ^a			
Cancer survivors $(N = 513)^b$				
Aging constructs	No. of deaths	Total	HR (95% CI) per 1 SD increase in Aging constructs	
		person-year	Model 2 ^d	Model 2 ^d
HannumAccel (SD = 5.48 years)	88	2,011	1.23 (1.04, 1.45)	1.34 (1.13, 1.58)
HorvathAccel (SD = 6.94 years)			1.19 (0.95, 1.49)	1.27 (1.02, 1.58)
LevineAccel (DNAmPhenoAge) (SD = 6.89 years)			1.48 (1.22, 1.80)	1.55 (1.26, 1.93)
GrimAgeAccel (SD = 4.66 years)			2.01 (1.55, 2.60)	2.09 (1.45, 3.00)
POA (SD = 0.09 years of physiological decline per one chronological year)			1.30 (1.03, 1.65)	1.13 (0.82, 1.57)
Controls $(N = 2,733)^b$				
Aging constructs	No. of deaths	Total	HR (95% CI) per 1 SD increase in Aging constructs	
		person-year	Model 1 ^c	Model 2 ^d
HannumAccel (SD = 5.11 years)	207	11,145	1.22 (1.03, 1.44)	1.20 (1.00, 1.44)
HorvathAccel (SD = 6.23 years)			1.08 (0.88, 1.32)	1.05 (0.85, 1.31)
LevineAccel (SD = 6.72 years)			1.15 (0.94, 1.39)	1.10 (0.89, 1.34)
GrimAgeAccel (SD = 4.65 years)			1.54 (1.32, 1.79)	1.42 (1.15, 1.74)
POA (SD = 0.09 years of physiological decline per one chronological year)			1.42 (1.26, 1.62)	1.30 (1.14, 1.49)

^aSample A includes participants who had measures of KDM-BA, PhenoAge, and SA. Sample B includes participants who had data on ECs. ^bControls are participants without a history of cancer in 2016. Cancer survivors are participants with a history of cancer in 2016.

^cModel 1 was adjusted for chronological age.

^dModel 2 was adjusted for chronological age, sex, race/ethnicity, BMI, smoking status, comorbidity index, and CMV infection.